BUZZ-Crescent Biopharma jumps after cancer drug partnership

Reuters12-04

** Shares of drugmaker Crescent Biopharma CBIO.O rise 36.5% to $18.30 premarket

** Co says it has formed an exclusive partnership with China's Kelun-Biotech to develop and market new cancer treatments

** Co is also raising $185 million from investors to fund clinical trials - CBIO

** Says deal gives Kelun-Biotech rights to co's experimental drug CR-001 in Greater China

** CBIO's CR-001 aims to boost immune response and block blood supply to tumors; SKB105 targets solid tumors, co says

** Both firms plan to test drugs alone and in combination; human trials for 3 drugs set for 2026, co says

** Up to last close, stock was down ~46% YTD

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2588888137?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-04 20:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588888137","market":"fut","top_or_hot":-1,"title":"BUZZ-Crescent Biopharma jumps after cancer drug partnership","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Crescent Biopharma jumps after cancer drug partnership </title></head><body><p>** Shares of drugmaker Crescent Biopharma <span>CBIO.O</span> rise 36.5% to $18.30 premarket </p><p>** Co says it has formed an exclusive partnership with China's Kelun-Biotech to develop and market new cancer treatments</p><p>** Co is also raising $185 million from investors to fund clinical trials - CBIO</p><p>** Says deal gives Kelun-Biotech rights to co's experimental drug CR-001 in Greater China</p><p>** CBIO's CR-001 aims to boost immune response and block blood supply to tumors; SKB105 targets solid tumors, co says</p><p>** Both firms plan to test drugs alone and in combination; human trials for 3 drugs set for 2026, co says</p><p>** Up to last close, stock was down ~46% YTD </p><p> (Reporting by Sahil Pandey in Bengaluru)</p><p> ((Sahil.Pandey@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Crescent Biopharma jumps after cancer drug partnership</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Crescent Biopharma jumps after cancer drug partnership\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-04 20:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Crescent Biopharma jumps after cancer drug partnership </title></head><body><p>** Shares of drugmaker Crescent Biopharma <span>CBIO.O</span> rise 36.5% to $18.30 premarket </p><p>** Co says it has formed an exclusive partnership with China's Kelun-Biotech to develop and market new cancer treatments</p><p>** Co is also raising $185 million from investors to fund clinical trials - CBIO</p><p>** Says deal gives Kelun-Biotech rights to co's experimental drug CR-001 in Greater China</p><p>** CBIO's CR-001 aims to boost immune response and block blood supply to tumors; SKB105 targets solid tumors, co says</p><p>** Both firms plan to test drugs alone and in combination; human trials for 3 drugs set for 2026, co says</p><p>** Up to last close, stock was down ~46% YTD </p><p> (Reporting by Sahil Pandey in Bengaluru)</p><p> ((Sahil.Pandey@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"002422","symbol_name":"科伦药业","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nL4N3XA0UJ:1","article_id":"2588888137","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588888137","pubTimestamp":1764851056,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Crescent Biopharma jumps after cancer drug partnership ** Shares of drugmaker Crescent Biopharma CBIO.O rise 36.5% to $18.30 premarket ** Co says it has formed an exclusive partnership with China's Kelun-Biotech to develop and market new cancer treatments** Co is also raising $185 million from investors to fund clinical trials - CBIO** Says deal gives Kelun-Biotech rights to co's experimental drug CR-001 in Greater China** CBIO's CR-001 aims to boost immune response and block blood supply to tumors; SKB105 targets solid tumors, co says** Both firms plan to test drugs alone and in combination; human trials for 3 drugs set for 2026, co says** Up to last close, stock was down ~46% YTD   ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"002422":"科伦药业","BK4139":"生物科技","BK0060":"抗癌","IVX.AU":"INVION LTD","LU1934453819.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"A\" (USD) ACC","LU0196878994.USD":"MANULIFE GF CHINA VALUE \"AA\" (USD) INC","BK7096":"制药","BK7508":"医药生物股","LU1979443071.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"AD\" (USDHDG) INC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","BK7509":"中概股","BK0239":"医药制造","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","06990":"科伦博泰生物-B","CBIO":"Crescent Biopharma Inc","BK1161":"生物科技"},"translate_title":"BUZZ-Crescent Biopharma在癌症药物合作后股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06990":0.9,"CBIO":0.9,"002422":0.9,"IVX.AU":0.9},"content_text":"BUZZ-Crescent Biopharma jumps after cancer drug partnership ** Shares of drugmaker Crescent Biopharma CBIO.O rise 36.5% to $18.30 premarket ** Co says it has formed an exclusive partnership with China's Kelun-Biotech to develop and market new cancer treatments** Co is also raising $185 million from investors to fund clinical trials - CBIO** Says deal gives Kelun-Biotech rights to co's experimental drug CR-001 in Greater China** CBIO's CR-001 aims to boost immune response and block blood supply to tumors; SKB105 targets solid tumors, co says** Both firms plan to test drugs alone and in combination; human trials for 3 drugs set for 2026, co says** Up to last close, stock was down ~46% YTD  (Reporting by Sahil Pandey in Bengaluru) ((Sahil.Pandey@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2588888137","isCrawlerRequest":true}